Creating value in the lives of the people we serve, now and into the future

UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.

Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge

Financial Guidance

The figures of the guidance 2025 as mentioned below were calculated on the same basis as the actual figures for 2024 and based on current rules and regulations.

2025 Revenue

at least € 7bn

Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, Expanded access in the U.S. for BIMZELX® with significantly faster conversion to paid scripts in H1, CIMZIA® H1 performance supported by exceptional / 
non-recurring items (not to repeat in H2), IRA and 340B impact across indications

2025 adj. EBITDA 

at least 30%

Continued gross margin improvement, operating leverage improvement, Operating Leverage improvement, continued growth of marketing and sales expenses driven by top-line growth and maintained investment in R&D

2025 Core EPS

at least € 7.25

based on an average of 190 million shares outstanding and tax rate of 20%

 

Contact UCB IR Team

investor-relations@ucb.com or a specific team member:

Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com



Sahar Yazdian, Investor Relations Lead

Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com

Diyana Mishu, Investor Relations Manager
Tel: +32 2 599 7446
E-mail: Diyana.Mishu@ucb.com

UCB IR App

ucb ir app
App Store


 

Google Play

×